The comparison of Filgrastim (Neupogen (R)), biosimilar filgrastim (Leucostim (R)) and Lenograstim (Granocyte (R)) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: A single center experience from Turkey


Sivgin S., Karakus E., KAYNAR L. , Kurnaz F. , Pala C., Keklik M. , ...More

TRANSFUSION AND APHERESIS SCIENCE, vol.48, no.3, pp.315-320, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 48 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1016/j.transci.2013.04.007
  • Title of Journal : TRANSFUSION AND APHERESIS SCIENCE
  • Page Numbers: pp.315-320

Abstract

Objectives and aim: Patients affected by hematological malignancies can often benefit from high dose chemotherapy followed by peripheral blood stem cells (PBSCs) transplantation. Different strategies have been used to mobilize an adequate number of PBSC, including granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy plus G-CSF. In this study, we aimed to compare the efficacy profile of different G-CSF agents including filgrastim (Neupogen (R)), biosimilar filgrastim (Leucostim (R)) and Lenograstim (Granocyte (R)) on CD34(+) mobilization in patients who underwent autologous hematopoietic stem cell transplantation (autoHSCT).